Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.67 |
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | CA4 | P22748 | 2/20 | 0.67 |
| ▸ | CA6 | P23280 | 2/20 | 0.67 |
| ▸ | CA5A | P35218 | 2/20 | 0.67 |
| ▸ | CA7 | P43166 | 2/20 | 0.67 |
| ▸ | CA9 | Q16790 | 2/20 | 0.67 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.67 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | PI4KA | P42356 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31279787 | 1.00 | CA12 (0.67) | CA12CA1CA2CA4CA6 | |
| SCHEMBL10535598 | 0.83 | CA12 (0.49) | CA12CA1CA2CA4CA6 | |
| SCHEMBL4063653 | 0.80 | CA2 (1.00) | CA12CA1CA2CA4CA6 | |
| SCHEMBL564713 | 0.80 | ALDH1A1 (0.47) | CA12CA1CA2CA4CA6 | |
| SCHEMBL11707092 | 0.79 | CA12 (0.62) | CA12CA1CA2CA4CA6 | |
| SCHEMBL1134478 | 0.78 | CA1 (0.67) | CA12CA1CA2CA4CA6 | |
| SCHEMBL2642532 | 0.78 | CA12 (0.60) | CA12CA1CA2CA4CA6 | |
| SCHEMBL26107943 | 0.77 | PI4KB (0.55) | CA12CA1CA2CA4CA6 | |
| SCHEMBL2645412 | 0.76 | PIK3CD (0.40) | CA12CA1CA2CA4CA6 | |
| SCHEMBL2572656 | 0.76 | ENPP2 (0.43) | CA12CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| CN-117813302-A | Substituted tetrahydrofuran-2-carboxamides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2002000661-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001064669-A1 | PYRAZOLE ETHER DERIVATIVES AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PRODUCTS INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001040216-A1 | HETEROCYCLO-ALKYLSULFONYL PYRAZOLE DERIVATIVES AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| EP-1104759-A1 | Heteroaryl phenyl pyrazole compounds as anti-inflammatory/analgesic agents | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| EP-1104758-A1 | Acetylene derivatives as anti-inflammatory/analgesic agents | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| US-4841036-A | COLORFAST, HEAT RESISTANCE | MITSUBISHI CHEMICAL INDUSTRIES, LIMITED (JP) | 1989-06-20 | — | — | US | disclosed |
| EP-0108570-B1 | DISAZO DYESTUFFS FOR CELLULOSE-CONTAINING FIBRES AND PROCESS FOR PREPARING THE DYESTUFF | MITSUBISHI KASEI CORPORATION (JP) | 1986-10-29 | — | — | EP | disclosed |
| EP-0121825-B1 | MONOAZO DYESTUFFS FOR CELLULOSE-CONTAINING FIBERS | MITSUBISHI KASEI CORPORATION (JP) | 1986-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | WNT3, WNT3A, WNT1 | CA12 4315/4885CA1 4705/4885CA2 2736/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | CA12 2134/4885CA1 1259/4885CA2 1253/4885 |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | WNT1, WNT3, WNT3A | CA12 3334/4885CA1 3972/4885CA2 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.